The differences in immunohistochemical expression of p53, bcl-2, bax, estrogen receptor
(ER), and progesterone receptor (PR) were evaluated in 40 endometrioid and 21 papillary …

Forty-two cases, including 21 uterine papillary serous carcinomas (UPSC) and 21 age-,
nuclear-grade-, and clinical-stage-matched uterine endometrioid carcinomas (UEC), were …

Objective The aim of this study was to determine whether immunohistochemical analysis of
molecular parameters can provide an alternative method for classification of endometrial …

The distinction between uterine serous and endometrioid carcinomas can usually be
achieved by morphologic examination alone. However, there are occasional …

In order to clarify the factors that affect growth of endometrial carcinoma,
immunohistochemical analyses of bcl-2, p53, sex steroid receptors, and Ki-67 were …

Diffuse p53 immunostaining distinguishes 85% of serous (Type II) from endometrioid (Type
I) carcinomas and is an independent marker for poor prognosis. Interobserver reproducibility …

On the basis of pathogenesis, two types of endometrial cancer can be recognized. Type 1
endometrial carcinomas are relatively indolent tumors that develop after prolonged estrogen …

There is accumulating evidence that immunohistochemical staining for p53 can identify
patients with endometrial carcinoma who have an adverse outcome, but the interpretation of …

AIM: To test which immunohistochemically detected tumour parameters are predictive of
outcome in endometrial carcinoma. METHODS: A retrospective study of 300 patients …

To elucidate the role of p53 abnormalities in endometrial tumorigenesis, a diverse group of
endometrial neoplasms and their putative precursors, atypical endometrial hyperplasia, and …